BSP Pharmaceuticals SpA
Location: Latina, Italy
Project: An integrated state-of-the-art site for antibody-drug conjugates (ADCs), drug substance (DS), and drug product (DP), from investigational new drug (IND) to commercial supply
The facility operates from Investigational New Drug through to commercial supply. The project was recognized for addressing one of the most persistent bottlenecks in antibody-drug conjugate (ADC) manufacturing: a highly fragmented supply chain. BSP has consolidated drug substance (DS) conjugation and sterile drug product (DP) fill-finish in one facility, with one quality system, eliminating multi-site handoffs that have historically complicated the clinical and commercial scale supply chain.
The Problem BSP Solved
The standard ADC manufacturing model requires shipping the antibody to one site, the highly potent toxin to another, performing conjugation, freezing the intermediate, and transporting it again to a separate fill-finish facility. Each handoff introduces cold chain exposure, logistics dependency, and potential delays that affect both product integrity and time-to-market. Achieving this level of integration at commercial scale is rare in the contract development and manufacturing organization (CDMO) sector. Most facilities handle either conjugation or fill-finish, not both, resulting in multi-vendor oversight and divided quality systems.
How BSP Solved It
Rather than distributing manufacturing across multiple sites and vendors, DS conjugation and DP fill-finish are co-located in Latina under a single quality system. The antibody and highly potent toxin is received, handled, and processed at the same facility, removing inter-site shipping entirely. As conjugation and fill-finish share a quality system, there is no multi-vendor oversight requirement and no transfer between regulatory frameworks. On-site storage down to -80°C eliminates cold chain exposure during transit.
Key Operational Achievements
- Good Laboratory Practice (GLP) Integration within Good Manufacturing Practice (GMP): BSP integrated a certified GLP laboratory directly within the GMP manufacturing core. Early-stage toxicology batches are run on the same commercial-grade equipment used for later-phase production, removing the technology transfer burden and re-validation requirements, as programs advance through development.
- Flexible, Purpose-Built Design: Conjugation capabilities span from 40g to 15kg, allowing the facility to support both clinical and commercial production volumes without equipment substitution. The facility is designed around the safe handling of highly toxic, unstable molecules, rather than being optimized solely for throughput.
- Safety: Cytotoxic compounds handled at the site carry an Occupational Exposure Limit (OEL) below 10 nanograms per cubic meter. Engineering controls and operational procedures are built strictly around this requirement. During project execution, BSP recorded a lost time injury rate of 0.14 across 1.4 million man-hours, supported by over 900 safety toolbox talks.
- Sustainability: The facility operates on 100 percent renewable electricity and reduced overall energy consumption by 18 percent over the past three years. This was achieved alongside the site's capacity expansion.
Ultimately, the Latina Scalo expansion sets a solid industry benchmark for supply chain resilience and speed-to-market. BSP Pharmaceuticals has demonstrated that highly complex ADC production can be secure, sustainable, and remarkably efficient by providing a practical, fully integrated solution to one of oncology manufacturing's most significant bottlenecks. For these reasons, BSP Pharmaceuticals is recognized as the 2026 ISPE FOYA Category Winner for Supply Chain.
Supply Partners and Key Participants
Manufacturer/Owner: BSP Pharmaceutical SpA
Engineer/Architect: Akkodis Italia
Commissioning, Qualifications, and Validation Services: Akkodis Italia
Construction Manager: Rebis Service Srl
Piping Subcontractor: Stilmas S.p.A.
HVAC Subcontractor: OC Srl
Automation and Control Supplier: Tecnoelectric
Major Equipment Supplier or Contractor:
- IMA Life
- Fedegari Autoclavi SpA
Additional Suppliers:
- Syntegon Telstar
- Sartorius Stedim Italy Srl